Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 27 | 2021 | 458 | 2.260 |
Why?
|
| Lung Neoplasms | 9 | 2020 | 414 | 1.040 |
Why?
|
| Breast Neoplasms | 12 | 2019 | 765 | 0.980 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2020 | 17 | 0.740 |
Why?
|
| Antibodies, Monoclonal | 10 | 2019 | 246 | 0.580 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2012 | 101 | 0.550 |
Why?
|
| Colorectal Neoplasms | 6 | 2016 | 215 | 0.510 |
Why?
|
| Aged | 39 | 2021 | 10314 | 0.460 |
Why?
|
| Taxoids | 7 | 2018 | 59 | 0.430 |
Why?
|
| Nitriles | 3 | 2017 | 23 | 0.430 |
Why?
|
| Triazoles | 3 | 2017 | 14 | 0.430 |
Why?
|
| Middle Aged | 39 | 2021 | 11839 | 0.430 |
Why?
|
| Disease-Free Survival | 14 | 2018 | 317 | 0.390 |
Why?
|
| Aged, 80 and over | 23 | 2021 | 3990 | 0.380 |
Why?
|
| Aminopyridines | 4 | 2019 | 6 | 0.370 |
Why?
|
| Purines | 4 | 2019 | 22 | 0.370 |
Why?
|
| Immunoconjugates | 3 | 2019 | 9 | 0.360 |
Why?
|
| Pyrimidines | 3 | 2020 | 65 | 0.350 |
Why?
|
| Adult | 29 | 2019 | 9380 | 0.340 |
Why?
|
| Multiple Myeloma | 2 | 2021 | 20 | 0.310 |
Why?
|
| Female | 37 | 2021 | 20015 | 0.310 |
Why?
|
| Treatment Outcome | 20 | 2019 | 3306 | 0.300 |
Why?
|
| Humans | 41 | 2021 | 32114 | 0.300 |
Why?
|
| Double-Blind Method | 5 | 2020 | 525 | 0.280 |
Why?
|
| Sirolimus | 4 | 2014 | 33 | 0.280 |
Why?
|
| Nanoparticles | 2 | 2018 | 52 | 0.280 |
Why?
|
| Receptor, erbB-2 | 6 | 2018 | 65 | 0.270 |
Why?
|
| Salvage Therapy | 2 | 2021 | 134 | 0.260 |
Why?
|
| Adenocarcinoma | 4 | 2015 | 308 | 0.250 |
Why?
|
| Neoplasm Metastasis | 9 | 2019 | 220 | 0.250 |
Why?
|
| Male | 29 | 2021 | 19217 | 0.240 |
Why?
|
| Neoplasm Staging | 9 | 2019 | 447 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 199 | 0.220 |
Why?
|
| Neoplasms | 3 | 2016 | 728 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 232 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 244 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 297 | 0.210 |
Why?
|
| Mutation | 2 | 2018 | 489 | 0.210 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 608 | 0.200 |
Why?
|
| Maximum Tolerated Dose | 6 | 2021 | 62 | 0.200 |
Why?
|
| Receptors, Estrogen | 6 | 2017 | 113 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2018 | 85 | 0.190 |
Why?
|
| Prostate-Specific Antigen | 2 | 2018 | 62 | 0.190 |
Why?
|
| Topotecan | 1 | 2020 | 17 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2016 | 14 | 0.180 |
Why?
|
| Membrane Glycoproteins | 3 | 2019 | 101 | 0.180 |
Why?
|
| Quinazolines | 5 | 2012 | 38 | 0.180 |
Why?
|
| Benzamides | 2 | 2018 | 50 | 0.180 |
Why?
|
| Postmenopause | 4 | 2017 | 430 | 0.180 |
Why?
|
| Pyrroles | 1 | 2020 | 55 | 0.180 |
Why?
|
| Imidazoles | 3 | 2015 | 91 | 0.170 |
Why?
|
| Receptors, Progesterone | 5 | 2017 | 72 | 0.170 |
Why?
|
| Androstadienes | 3 | 2013 | 17 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 940 | 0.170 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2018 | 2 | 0.160 |
Why?
|
| CREB-Binding Protein | 1 | 2018 | 4 | 0.160 |
Why?
|
| Survival Rate | 8 | 2019 | 877 | 0.160 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 14 | 0.160 |
Why?
|
| Camptothecin | 5 | 2016 | 51 | 0.160 |
Why?
|
| Drug Administration Schedule | 5 | 2021 | 276 | 0.160 |
Why?
|
| Leukopenia | 1 | 2017 | 8 | 0.150 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 69 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 29 | 0.150 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 2 | 2015 | 3 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 261 | 0.150 |
Why?
|
| Naphthalenes | 2 | 2015 | 40 | 0.150 |
Why?
|
| Melanoma | 1 | 2019 | 164 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 42 | 0.140 |
Why?
|
| Pyrrolidinones | 1 | 2016 | 5 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 214 | 0.130 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2016 | 7 | 0.130 |
Why?
|
| Quinolines | 1 | 2016 | 21 | 0.130 |
Why?
|
| Drug Carriers | 1 | 2016 | 21 | 0.130 |
Why?
|
| Resorcinols | 1 | 2015 | 6 | 0.130 |
Why?
|
| Isoxazoles | 1 | 2015 | 3 | 0.130 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 9 | 0.130 |
Why?
|
| Quality of Life | 2 | 2020 | 946 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 104 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 7 | 0.120 |
Why?
|
| Organoplatinum Compounds | 4 | 2012 | 46 | 0.120 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2013 | 9 | 0.120 |
Why?
|
| ras Proteins | 2 | 2012 | 10 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2012 | 85 | 0.110 |
Why?
|
| Bone Remodeling | 1 | 2013 | 9 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 367 | 0.110 |
Why?
|
| Bone Density Conservation Agents | 1 | 2013 | 23 | 0.110 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Pyrimidinones | 1 | 2012 | 4 | 0.110 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 753 | 0.110 |
Why?
|
| Pyridones | 1 | 2012 | 10 | 0.110 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2012 | 4 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 134 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 111 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2014 | 37 | 0.100 |
Why?
|
| Prognosis | 4 | 2019 | 1497 | 0.100 |
Why?
|
| Nausea | 3 | 2018 | 53 | 0.100 |
Why?
|
| Bone Density | 1 | 2013 | 205 | 0.100 |
Why?
|
| Fatigue | 3 | 2018 | 85 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2265 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 105 | 0.090 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 2 | 0.090 |
Why?
|
| Lymphoma, Follicular | 1 | 2009 | 17 | 0.080 |
Why?
|
| Oligopeptides | 2 | 2021 | 45 | 0.080 |
Why?
|
| Disease Progression | 3 | 2015 | 594 | 0.070 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 25 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 40 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2006 | 67 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2006 | 67 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2007 | 114 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 633 | 0.070 |
Why?
|
| Diarrhea | 2 | 2018 | 60 | 0.070 |
Why?
|
| Carboplatin | 3 | 2012 | 48 | 0.070 |
Why?
|
| Deoxycytidine | 3 | 2013 | 68 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2018 | 162 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2007 | 201 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 190 | 0.060 |
Why?
|
| Leucovorin | 3 | 2012 | 24 | 0.060 |
Why?
|
| Fluorouracil | 3 | 2012 | 81 | 0.060 |
Why?
|
| Young Adult | 3 | 2019 | 2665 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 898 | 0.060 |
Why?
|
| Pyrazines | 2 | 2014 | 13 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2012 | 67 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1538 | 0.050 |
Why?
|
| Premedication | 1 | 2021 | 13 | 0.050 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 23 | 0.050 |
Why?
|
| Time Factors | 2 | 2017 | 2151 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 43 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2010 | 21 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 21 | 0.040 |
Why?
|
| Guanine | 2 | 2007 | 15 | 0.040 |
Why?
|
| Glutamates | 2 | 2007 | 11 | 0.040 |
Why?
|
| Breast | 1 | 2017 | 68 | 0.040 |
Why?
|
| Dyspnea | 1 | 2017 | 33 | 0.040 |
Why?
|
| Arthralgia | 1 | 2017 | 33 | 0.040 |
Why?
|
| Mastectomy | 1 | 2017 | 64 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 166 | 0.030 |
Why?
|
| Hot Flashes | 1 | 2017 | 48 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2016 | 24 | 0.030 |
Why?
|
| New Zealand | 1 | 2015 | 9 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 19 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 28 | 0.030 |
Why?
|
| North America | 1 | 2015 | 32 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 21 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 72 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 82 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 41 | 0.030 |
Why?
|
| Prednisone | 1 | 2015 | 61 | 0.030 |
Why?
|
| Indoles | 1 | 2015 | 56 | 0.030 |
Why?
|
| United States | 3 | 2012 | 3976 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2014 | 16 | 0.030 |
Why?
|
| Neutropenia | 1 | 2014 | 29 | 0.030 |
Why?
|
| Anemia | 1 | 2014 | 58 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1199 | 0.030 |
Why?
|
| Alopecia | 1 | 2014 | 31 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 6 | 0.030 |
Why?
|
| Receptors, Steroid | 1 | 2013 | 9 | 0.030 |
Why?
|
| Viscera | 1 | 2013 | 17 | 0.030 |
Why?
|
| Stomatitis | 1 | 2013 | 18 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 30 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 63 | 0.030 |
Why?
|
| Depression | 1 | 2017 | 445 | 0.030 |
Why?
|
| Procollagen | 1 | 2013 | 7 | 0.030 |
Why?
|
| Fractures, Spontaneous | 1 | 2013 | 16 | 0.030 |
Why?
|
| Bone Resorption | 1 | 2013 | 12 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2013 | 9 | 0.030 |
Why?
|
| Exanthema | 1 | 2013 | 21 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 38 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 105 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2013 | 42 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 538 | 0.030 |
Why?
|
| Anilides | 1 | 2012 | 10 | 0.030 |
Why?
|
| Albumins | 1 | 2012 | 45 | 0.030 |
Why?
|
| Epothilones | 1 | 2012 | 3 | 0.030 |
Why?
|
| Half-Life | 1 | 2012 | 23 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2013 | 82 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 17 | 0.030 |
Why?
|
| Pyridines | 1 | 2012 | 76 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2012 | 27 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2012 | 93 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2012 | 187 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 301 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 472 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 259 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 36 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 510 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 112 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 40 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 35 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2009 | 8 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 960 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 294 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2007 | 4 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2007 | 3 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2007 | 4 | 0.020 |
Why?
|
| Piperazines | 1 | 2007 | 54 | 0.020 |
Why?
|
| Heart Failure | 1 | 2013 | 639 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 3880 | 0.020 |
Why?
|
| Cisplatin | 1 | 2006 | 76 | 0.020 |
Why?
|
| Adolescent | 1 | 2014 | 3568 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2006 | 483 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2010 | 3510 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 2484 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 7542 | 0.010 |
Why?
|